Celcuity Inc. experienced a significant increase in stock value following the release of positive findings from the Phase 3 VIKTORIA-1 trial. The trial focused on evaluating the effectiveness and safety of gedatolisib in combination with fulvestrant, with or without palbociclib, compared to fulvestrant alone. This study targeted patients with HR-positive/HER2-negative advanced breast cancer who had previously experienced resistance to endocrine therapy. The results showed a remarkable improvement in progression-free survival (PFS) with the gedatolisib triplet, reducing the risk of disease progression or death by 76% compared to fulvestrant alone. Additionally, the gedatolisib doublet demonstrated a 67% reduction in the risk of disease progression or death. These findings mark a significant advancement in the treatment of HR+/HER2- advanced breast cancer.
Read more from benzinga.com